Compare Synopsys, Inc. (SNPS) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Synopsys, Inc. vs TransMedics Group Inc — how do they compare? Synopsys, Inc. trades at $509.99 (market cap $95.39B), while TransMedics Group Inc trades at $77.87 (market cap $2.74B). The key difference: Synopsys, Inc. is far larger — about 34.8× TransMedics Group Inc's market cap, and Synopsys, Inc. is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Synopsys, Inc. for 71 Days and TransMedics Group Inc for 24 Days on average.
| SNPS | TMDX | |
|---|---|---|
Market Cap | $95.39B | $2.74B |
Volume | 3,374,903 | 949,331 |
Sector | Technology | Health |
52-Week High | $534.56 | $150.42 |
52-Week Low | $367.70 | $61.99 |
Typical Hold Time | 71 Days | 24 Days |
Enterprise Value | $102.62B | $3.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Synopsys (SNPS) trades at $497.75, down 0.98% on the day, but maintains a strong bullish technical trend with support at $492. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of $3.91 exceeding the $3.67 estimate. Recent investor day announcements highlighted AI partnerships with OpenAI and Amazon, driving a 13% stock surge and raising long-term growth expectations. Valuation metrics show a high P/E of 86.87, reflecting premium pricing for growth prospects.
The outlook for SNPS is positive, fueled by AI-driven demand for chip design software and strategic acquisitions like Ansys. Investment opportunities include exposure to the expanding custom silicon market and recurring revenue growth. Key risks involve elevated valuation multiples, integration challenges from acquisitions, and competitive pressures in the EDA software space. Analyst consensus is strongly bullish with a $572.54 price target, indicating 15% upside potential.
TMDX trades at $79.00, down 2.55% amid bearish technical signals. The stock shows strong profitability with 22.69% net margin and 36.28% ROE, though recent earnings misses and margin compression from 2025 to 2026 raise concerns. Analyst consensus remains bullish with a $99.75 price target, but multiple legal investigations into fiduciary duties create uncertainty. Revenue growth continues with 2026 guidance at $668M.
The stock presents a growth opportunity with analyst upside potential, but faces near-term headwinds from earnings volatility and legal scrutiny. Execution on 2026 guidance and resolution of governance concerns will be critical for sustained momentum. Current valuation at 20.47 P/E appears reasonable given growth prospects if operational targets are met.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Synopsys, Inc.
Synopsys is a provider of electronic design automation software, intellectual property, and software integrity products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. The firm's growing SI business allows customers to continuously manage and test the code base for security and quality. Synopsys' comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.
Read more on SNPS →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
